Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroOne Medical TechnologiesNMTC -6.47%21 Equity-to-Asset is 0.61 as of Jun. 2026, which is 15% above its 10-year median of 0.53. GuruFocus rates NMTC with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 852 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks worse than 53.05% on this metric.
NeuroOne Medical Technologies (NAS:NMTC) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
NeuroOne Medical Technologies Equity-to-Asset Related Terms
NeuroOne Medical Technologies Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroOne Medical Technologies Equity-to-Asset Chart
NMTC vs PMI, HSCS, IRIX: Equity-to-Asset Comparison
For the Medical Devices subindustry, NeuroOne Medical Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroOne Medical Technologies Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's Equity-to-Asset falls into.
NeuroOne Medical Technologies Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroOne Medical Technologies (NMTC) has a Equity-to-Asset of 0.61 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on NeuroOne Medical Technologies and its competitors. This is 15% above median its historical median of 0.53. According to the industry distribution chart, NeuroOne Medical Technologies ranks #452 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 53.1%.
Is NeuroOne Medical Technologies' Equity-to-Asset too high?
NeuroOne Medical Technologies' current Equity-to-Asset of 0.61 is 15% above median its 10-year median of 0.53. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. NeuroOne Medical Technologies' value of 0.61 is 4.7% below this industry median. Based on the distribution chart, NeuroOne Medical Technologies ranks #452 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NeuroOne Medical Technologies has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' Equity-to-Asset compare to PMI and HSCS?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #452 out of 852 companies for Equity-to-Asset. This places NeuroOne Medical Technologies in the lower half of its industry. The industry median Equity-to-Asset is 0.64. NeuroOne Medical Technologies' value of 0.61 is 4.7% below this benchmark. While the company's 10-year median is 0.53 vs. the industry median of 0.64, NeuroOne Medical Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroOne Medical Technologies's current Equity-to-Asset of 0.61 is 4.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on NeuroOne Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroOne Medical Technologies's current Equity-to-Asset is 0.61, which is 15% above median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
NeuroOne Medical Technologies (NMTC) has a current Equity-to-Asset of 0.61. The current Equity-to-Asset is 0.61, which is 15% above median its 10-year median of 0.53 and 4.7% below the Medical Devices & Instruments industry median of 0.64. NeuroOne Medical Technologies' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current Equity-to-Asset is 0.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
21GF Score
Get the complete analysis for NMTC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMTC has been successfully added to your 
